Biote is a practice-building company focused on hormone replacement therapy (HRT). Biote does not treat patients directly — instead, it provides licensed healthcare practitioners with a comprehensive platform to add an HRT practice to their existing medical office. The core offering, the "Biote Method," includes mandatory clinical training and certification, proprietary clinical decision support software (CDSS) that suggests individualized hormone dosing, inventory management software, marketing support, and access to compounding facilities that supply bioidentical hormone pellets. The primary treatment modality is subcutaneous hormone pellets implanted in a brief in-office procedure two to three times per year. As of December 2025, Biote had over 9,200 certified practitioners across more than 5,300 partnered clinics. Biote's business model is analogous to a franchise: it charges a per-procedure service fee each time a certified practitioner performs a pellet insertion, making procedure volume and clinic count the primary revenue drivers. Because procedures are paid out-of-pocket by patients — not through insurance — Biote avoids payor concentration risk. A secondary revenue stream is a line of 26 private-label dietary supplements sold wholesale to practitioners and directly to consumers via e-commerce and Amazon. Biote acquired Asteria Health, a 503B outsourcing facility, in 2024, enabling internal pellet manufacturing and improving gross margins. Growth is driven by adding new clinics and increasing procedure volume within existing ones.